Insulet Corp

Insulet Corp’s CEO sells 2,000 shares in a routine SEC Form 4, with standard tax‑withholding and no impact on strategy or governance.

Insulet’s CEO buying shares signals confidence, but the real story lies in its growing insulin‑pump business, regulatory challenges, and the race toward AI‑driven diabetes care.

Insulet Corp’s 4% stock dip amid a tech rally still highlights solid fundamentals—score 83, strong earnings outlook, and ETF upside potential.

Insulet’s Q1 2026 results show a 12.4% revenue lift, 46% net income jump, and $300 M share buyback, driven by Omnipod growth and cost control, promising strong shareholder value and patient‑care innovation.

Insulet Corp launches a pivotal trial to refine its closed‑loop insulin system, promising lower HbA1c, better patient adoption, and a strategic edge amid ETF inclusion and macro‑economic uncertainty.

Insulet Corp’s shares fell as Medtronic and Tandem launch competitors, yet the company plans a 20‑22% Q1 revenue rise by expanding in Type 2 markets and new regions while addressing a $40 m recall of Omnipod 5 units.

Insulet Corp’s ETF‑driven stability shows how macro‑shifts and competitive pressures shape mid‑cap equity value—balanced fundamentals, growing digital health focus, and index‑linked risk revealed.

Insulet Corp’s recent share dip sparks analyst focus on ETF visibility, undervalued metrics and institutional flows, revealing a potential rebound once earnings and product updates surface.

Insulet Corp faces SEC scrutiny over alleged disclosure fraud, causing sharp trading spikes and a slide in share price, raising investor and regulatory concerns about future valuations.

Insulet faces a securities‑fraud probe and manufacturing setbacks that could slash EPS 65 %. Explore regulatory risks, supply‑chain gaps, and strategic fixes for investors.